Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979661 · ClinicalTrials.gov registry record · Early Phase 1
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT06979661 is a Early Phase 1 study that has not yet begun recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 25 participants.
The verdict
NCT06979661, a Early Phase 1 study, has not yet begun recruiting, sponsored by Rutgers, The State University of New Jersey.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned therapy. Secondary Objectives: Evaluate personalized postoperative Chemo/ICPI/Targeted Therapies/Radiation Therapy in clearing ctDNA Evaluate the disease-free survival (DFS) and overall survival (OS) of stage II/III lung cancer patients with postoperative ctDNA positive status Exploratory Objective: Evaluate radiomics features based on serial CT thoracic CT scans to determine if radiomic features can be associated with ctDNA positivity/negativity.
Interventions
- DIAGNOSTIC_TEST Haystack™ ctDNA Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2029-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979661
The ClinicalTrials.gov registry entry for NCT06979661 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Haystack™ ctDNA Assay is the first listed.
NCT06979661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06979661 about?
NCT06979661 is a clinical study titled "Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy". Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned the...
What is the current status of trial NCT06979661?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2025-06-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT06979661?
The interventions under investigation include: Haystack™ ctDNA Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06979661?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.